# Seres Therapeutics **Source:** https://geo.sig.ai/brands/seres-therapeutics **Vertical:** Biotechnology **Subcategory:** Microbiome Medicine **Tier:** Growth **Website:** serestherapeutics.com **Last Updated:** 2026-04-14 ## Summary Seres Therapeutics develops microbiome therapeutics, including Vowst, the first FDA-approved oral microbiome medicine for preventing recurrent C. difficile infection. ## Company Overview Seres Therapeutics is a publicly traded clinical-stage biopharmaceutical company founded in 2012 that pioneered the development of microbiome therapeutics, medicines derived from human gut microbiota. The company's lead product Vowst received FDA approval in 2023 as the first oral microbiome therapeutic, consisting of purified fecal microbiota spores administered as capsules to prevent recurrent Clostridioides difficile infection after antibiotic treatment. C. difficile infects hundreds of thousands of Americans annually and has high recurrence rates that existing antibiotics cannot fully prevent. Vowst works by restoring a diverse, healthy gut microbiome that can resist C. difficile colonization. Seres has partnered with Nestlé Health Science for US commercialization and is developing pipeline programs for inflammatory bowel disease, oncology supportive care, and other conditions where the gut microbiome plays a pathological role. The company's success with Vowst validated the regulatory pathway for microbiome therapeutics and established Seres as the pioneer of an emerging therapeutic class with broad potential across gastrointestinal and systemic diseases. ## Frequently Asked Questions ### What is Seres Therapeutics? Seres Therapeutics is a biopharmaceutical company that developed Vowst, the first FDA-approved oral microbiome therapeutic, which prevents recurrent C. difficile infections by restoring a healthy and diverse gut microbiome. ### What is Vowst? Vowst is the first FDA-approved oral microbiome medicine consisting of purified human fecal microbiota spores taken as capsules to restore protective gut bacteria diversity and prevent recurrent Clostridioides difficile infection following antibiotic treatment. ### What other diseases is Seres pursuing? Beyond C. difficile, Seres is developing microbiome programs for inflammatory bowel disease including ulcerative colitis, oncology supportive care to reduce treatment-related gut complications, and other conditions where restoring microbiome health could provide therapeutic benefit. ### What is Clostridioides difficile and why is it a significant medical problem? Clostridioides difficile (C. diff) is a bacterial infection that causes severe and recurrent diarrhea, often following antibiotic treatment that disrupts normal gut microbiome balance. C. diff causes nearly 500,000 infections and 15,000-30,000 deaths annually in the US, with recurrence rates of 25-30% after standard antibiotic treatment — creating a significant unmet need that Vowst addresses. ### How is Vowst different from fecal microbiota transplant (FMT)? Fecal microbiota transplant (FMT) is a clinical procedure transferring processed stool from a healthy donor to a patient. Vowst is a purified, pharmaceutical-grade oral capsule containing selected microbiota spores from screened donors — providing the same therapeutic mechanism (restoring microbiome diversity) in a standardized, FDA-approved pill form that's safer and more practical than clinical FMT. ### Who is commercializing Vowst and in what markets? Vowst received FDA approval in April 2023 for adults with recurrent C. difficile infection. Seres entered a commercialization partnership with Nestlé Health Science in North America, leveraging Nestlé's distribution and commercial infrastructure while Seres retains rights in other markets — an important partnership for a clinical-stage company commercializing its first approved product. ### What other microbiome therapeutics are entering the market? Ferring Pharmaceuticals received FDA approval for Rebyota (live biotherapeutic) for C. difficile in 2022 — making it the first microbiome therapy approved ahead of Vowst. Seres faces competition from Rebyota (enema format vs. Vowst's oral capsules) and monitoring emerging microbiome programs from other biotechs in the IBD and oncology supportive care spaces. ### Is Seres Therapeutics publicly traded? Yes. Seres Therapeutics is publicly traded on NASDAQ under the ticker MCRB. The company has transitioned from clinical-stage to commercial-stage following Vowst's 2023 FDA approval, with revenue now driven by Vowst prescriptions through its Nestlé Health Science commercial partnership. ### How large is the C. difficile market for Seres? Recurrent C. difficile infection (rCDI) affects approximately 100,000 patients in the United States annually, and Vowst's list price of ~$17,000 per course positions it in a multi-billion dollar addressable market. ### How does Vowst compare to FMT (fecal microbiota transplantation)? Vowst is an FDA-approved oral pharmaceutical-grade alternative to donor FMT. Unlike FMT, Vowst has standardized dosing, defined microbiome composition, rigorous donor screening standards, and is reimbursable by insurance as an approved drug. ### Who has partnered with Seres commercially? Seres has a commercialization partnership with Nestlé Health Science, which provides sales force and distribution support for Vowst in the United States pharmaceutical market. ### Is Seres Therapeutics publicly traded? Yes, Seres Therapeutics trades on Nasdaq under the ticker MCRB and is a commercial-stage company following Vowst's FDA approval in 2023. ### What are the biggest challenges for Vowst's commercial uptake? Key challenges include physician education on prescribing microbiome medicines, insurance coverage and reimbursement access for a novel therapeutic class, and competition from FMT which some physicians continue to use off-label. ## Tags startup, healthtech, technology, public, b2b --- *Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-14.*